sales@dcchemicals.com
DMA4-H228
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| DMA4-H228 | 66.67 | Ionizable lipid |
| Cholesterol | 25.67 | Sterol |
| DSPC | 6.67 | Helper phospholipid |
| DMG-PEG2000 | 1 | PEG lipid |
| Reported total | 100.01 | Source values retained |
Component molecular weights and calculated amounts
Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| DMA4-H228 | 66.663 | 78.5537 | 79.1420 | ||
| Cholesterol | 25.667 | 30.2456 | 11.6944 | ||
| DSPC | 6.669 | 7.8589 | 6.2097 | ||
| DMG-PEG2000 | 1.000 | 1.1782 | 2.9539 |
Calculated total: 100.0000 mg lipid.
Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.
Literature-reported performance for the cited formulation
Literature-reported97.9% in the representative Fig.1E readout0.25 mg/kg FLuc mRNA IV; screen n=2; not percent injected dose · 6 hMain PDF p.4, Fig.1D-E
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetDimethylamino-based synthetic lipidoid nanoparticles for selective mRNA delivery to splenic antigen-presenting cells. DOI: 10.1016/j.jconrel.2025.113737 DOI: 10.1016/j.jconrel.2025.113737
Main article supplied; SI not supplied. 10:1 is ionizable-lipid:RNA by weight, not total-lipid:RNA or N/P. Rounded component values total 100.01.
Main article supplied; SI not supplied. 10:1 is ionizable-lipid:RNA by weight, not total-lipid:RNA or N/P. Rounded component values total 100.01.